Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results -- Company Announces Webcast Presentations at Upcoming Conference -- Canaccord Genuity Global Growth Conference 2013 Business Wire SEATTLE -- July 15, 2013 July 15, 2013-- Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Thursday, August 8, 2013, at 4:30 p.m. EDT to review second quarter financial results. Access to the discussion may be obtained as follows: Time: 4:30 p.m. EDT / 1:30 p.m. PDT Date: August 8, 2013 Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international); conference pass code: 18807239 Webcast: www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 18807239. The replay will be available from 7:30 p.m. EDT on Thursday, August 8, until 11:59 p.m. EDT on Wednesday, August 14. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com. Dendreon Corporation also announced that management will present at the following conference: *Canaccord Genuity 33rd Annual Growth Conference in Boston, MA, on August 14 at 9:00 a.m. EDT The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website. About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. Contact: Dendreon Corporation Corporate Communications Lindsay Rocco, 862-596-1304 firstname.lastname@example.org or Investor Relations Nicole Soley, 206-455-2220 InvestorRelations@dendreon.com
Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results
Press spacebar to pause and continue. Press esc to stop.